Berberis aristata/Silybum marianumfixed combination on lipid profile and insulin secretion in dyslipidemic patients

Abstract

Berberis aristata/Silybum marianum is effective and safe in improving lipid profile and insulin secretion in euglycemic dyslipidemic patients.

Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial

“…As compared with monotherapies, the combination showed an improved lipid-lowering effect with 31.8% reduction of serum LDL-C, and similar efficacies were observed in the reduction of TC as well as Tg in patients. The positive effects of Berberis aristata on lipid profile were already reported by our group, in a study previously published where Berberol R reduced lipid profile compared to placebo; in particular, we recorded a TC reduction of 23.2% and a LDL-C reduction of 32.2% (Derosa et al 2013c). This reduction was higher compared to berberine alone that gave a TC reduction of 10.2% and a LDL-C reduction of 14.6% (11%), probably due to a synergic effect with Silybum marianum.…”

Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial

“…In previous studies where we tested a nutraceutical combination containing Berberis aristata combined with Silybum marianum , we reached a LDL reduction of about 24%, and also a decrease of TC and Tg, similar to the current results [6,7]. When we previously tested a nutraceutical combination of monacolins + Coenzime-Q10, instead, we observed a reduction in total cholesterol and LDL-C of about 22%, but no effects on HDL-C and Tg were recorded [13].…”

“…To avoid statins’ side effects, often physicians consider the use of hypocholesterolemic nutraceutical agents in subjects at low cardiovascular risk [4,5]. Among nutraceuticals, the combination of Berberis aristata 588 mg and Silybum marianum 105 mg largely proved to be effective and safe [6,7,8]. …”

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies

“…Thus, the absorption of BBR in the presence of P-gp inhibitors significantly increases both in in vivo and in vitro models, resulting in a markedly increased hypoglycemic effect [26]. To increase BBR bioavailability in humans, a combination of BBR with Silybum marianum extract, a P-gp inhibitor, has been tested in dyslipidemic patients, resulting in an improved lipid profile and insulin secretion (Table 5) [112].…”